Welcome to our dedicated page for Oscar Health SEC filings (Ticker: OSCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oscar Health, Inc. (NYSE: OSCR) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret complex documents. Oscar identifies itself in these filings as a healthcare technology company whose Class A common stock trades on the New York Stock Exchange under the symbol OSCR. Through its reports, investors can review how the company structures its health insurance operations, technology initiatives, and capital markets activities.
Oscar’s annual reports on Form 10-K and quarterly reports on Form 10-Q provide overviews of its Individual & Family health plans, health technology solutions under the +Oscar brand, risk factors, and detailed financial statements. These core filings typically include information on revenues, medical costs, selling, general, and administrative expenses, membership metrics, and key non-GAAP measures such as Adjusted EBITDA, along with management’s discussion of business drivers.
The company’s current reports on Form 8-K offer more targeted updates. Recent 8-K filings describe quarterly financial results, reaffirmed guidance, and capital structure actions such as the issuance of 2.25% Convertible Senior Subordinated Notes due 2030, related capped call transactions, and an exchange agreement involving 7.25% Convertible Senior Notes due 2031. Other 8-Ks detail amendments to investment agreements, the planned termination of a revolving credit facility in connection with a notes offering, and changes to executive employment agreements and compensation structures.
Investors can also use this page to access information on convertible debt terms, events of default, subordination provisions, and potential share dilution from note conversion, all of which are described in Oscar’s indentures and related exhibits. Stock Titan’s AI summaries help explain the implications of these filings, highlight key sections of lengthy documents, and surface important items such as changes in guidance, financing transactions, and governance-related disclosures. This makes it easier to understand how Oscar’s regulatory filings relate to its health insurance operations, technology platform, and long-term financial strategy.
Oscar Health, Inc. reported an insider stock sale by a senior officer. On 12/02/2025, the President of Oscar Insurance sold 7,338 shares of Class A common stock at a weighted average price of $16.59 per share. After this transaction, the reporting person beneficially owns 172,527 shares directly.
The sale was made under a pre-arranged Rule 10b5-1 trading instruction entered into on August 8, 2025 and was intended to cover the officer’s tax withholding obligations related to the vesting of previously granted equity awards. The shares were sold in multiple trades at prices ranging from $16.37 to $16.78.
Oscar Health, Inc. reported that its Chief Financial Officer sold 25,135 shares of Class A common stock on 12/02/2025 at a weighted average price of $16.59 per share. The sale was made under a pre-arranged Rule 10b5-1 instruction letter entered into on August 8, 2025, to cover the executive’s tax withholding obligations related to the vesting of previously granted equity awards.
Following this transaction, the CFO beneficially owns 1,351,034 shares of Oscar Health Class A common stock, held directly.
Oscar Health, Inc. (OSCR) reported an insider stock sale by its Chief Accounting Officer. On 12/02/2025, the officer sold 4,149 shares of Class A common stock in an open-market transaction coded as a sale. The weighted average price was $16.59 per share, with individual trades occurring between $16.37 and $16.78.
After this transaction, the officer beneficially owned 203,450 shares of Oscar Health Class A common stock. The sale was carried out under a Rule 10b5-1 instruction letter dated August 8, 2025, and was intended to satisfy tax withholding obligations upon the vesting of previously granted equity awards.
OSCR filed a notice of proposed sale covering 28,737 shares of its Class A Common Stock, to be sold through Morgan Stanley Smith Barney LLC on the NYSE with an aggregate market value of $480,770.01. The approximate sale date indicated is 12/02/2025.
The shares relate to 54,849 shares of Class A Common Stock acquired on 12/01/2025 through vesting of restricted stock units under a registered plan in exchange for services rendered. The filing notes that 229,010,000 shares of this class were outstanding, providing context for the size of the planned sale.
Oscar Health (OSCR) filed a notice of proposed insider share sales under Rule 144. The filing covers a planned sale of 8,398 shares of Class A common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $140,498.54 at the time of the notice. The issuer had 229,010,000 shares of Class A common stock outstanding.
The securities to be sold were acquired on 12/01/2025 as restricted stock units vesting under a registered plan, in consideration for services rendered, with 14,168 shares acquired on that date. The person for whose account the securities are to be sold represents that they are not aware of any material adverse, non‑public information about Oscar Health’s current or prospective operations.
Oscar Health (OSCR) filed a notice that an affiliated holder plans to sell Class A common stock under Rule 144. The filing reports an intended sale of 2,123 Class A shares through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $35,517.79 at the time of the notice. The issuer had 229,010,000 shares outstanding of this class, giving context to the size of the planned sale.
The shares to be sold come from restricted stock units that vested under a registered plan on 12/01/2025, with a total of 5,118 shares acquired on that date as consideration for services rendered. The signer represents that they are not aware of any non-public material adverse information about Oscar Health’s current or future operations, consistent with Rule 144 requirements.
OSCR received a notice that an insider plans to sell Class A common stock under Rule 144. Mario Schlosser intends to sell 22,195 Class A shares on the NYSE through Morgan Stanley Smith Barney LLC, with an aggregate market value of 371,322.35. The issuer has 229,010,000 Class A shares outstanding.
The shares to be sold were acquired on 12/01/2025 as 43,209 restricted stock units that vested under a registered plan in exchange for services rendered. Over the past three months, Schlosser has already sold Class A shares in several transactions: 395,000 shares on 09/22/2025 for gross proceeds of 7,279,850.00, 286,182 shares on 11/11/2025 for 4,369,999.14, and 105,300 shares on 11/12/2025 for 1,584,765.00.
T. Rowe Price Investment Management, Inc. filed Amendment No. 1 to a Schedule 13G reporting its beneficial ownership in Oscar Health, Inc. (Class A). The firm reports 8,322,004 shares of common stock, representing 3.7% of the class, with the Date of Event listed as 09/30/2025.
The filing lists sole voting power over 8,297,290 shares and sole dispositive power over 8,322,004 shares, with no shared voting or dispositive power. It is filed as an investment adviser in accordance with Rule 13d‑1(b). The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filer indicates ownership of 5 percent or less of the class.
Oscar Health (OSCR): Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., and James E. Flynn filed Amendment No. 3 to Schedule 13G reporting 0 shares and 0% beneficial ownership of Oscar Health’s Class A Common Stock.
The filing shows no sole or shared voting or dispositive power for any reporting person. The stated Date of Event is 09/30/2025, and each certifies the securities were not acquired or held to change or influence control.
Oscar Health (OSCR) reported insider activity by its President of Technology & CTO, who also serves as a director. On 11/11/2025 and 11/12/2025, the insider exercised stock options at $6.36 per share and converted Class B into Class A, then sold shares to cover the cost of exercise and tax withholding.
The insider sold 286,182 Class A shares at a weighted average price of $15.27 on 11/11/2025 and 105,300 shares at a weighted average price of $15.05 on 11/12/2025. Following the transactions, the insider directly owned 501,148 Class A shares. The option referenced is fully vested and expires on December 7, 2025. The filing also lists indirect holdings of Class A shares held by related trusts.